Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IMV Stock Summary
In the News
IMV Inc. (IMV) Q4 2022 Earnings Call Transcript
IMV Inc. (NASDAQ:IMV ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Andrew Hall - Chief Executive Officer Brittany Davison - Chief Accounting Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Doug Loe - Leede Jones Gable Operator Good day and thank you for standing by.
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results.
IMV, Inc. (IMV) Q3 2022 Earnings Call Transcript
IMV, Inc. (NASDAQ:IMV ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Joseph Pantginis - H.C. Wainwright & Co. Paul Stewardson - IA Capital Markets Operator Good day and thank you for standing by.
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.
IMV Inc. to Present at Two Investor Conferences in September
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV's executive management team will be presenting at two investor conferences in September. Please find additional details on the conferences below. H.C. Wainwright 24th Annual Global Investment Conference, New York City
IMV Inc. (IMV) CEO Andrew Hall on Q2 2022 Results - Earnings Call Transcript
IMV Inc. (NASDAQ:IMV ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Brittany Davison - Senior Vice President of Finance Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Medical Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the IMV Second Quarter 2022 Earnings Call.
IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, August 11, 2022, at 8:00 a.m. ET to discuss the company's 2022 second quarter financial and operational results. Financial analysts are invited to join
IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV's executive management team will be participating in person at the H.C. Wainwright Global Investment Conference, which will be held in person and virtually May 23-26, 2022 in Miami, FL. H.C. Wainwright Global Investmen
IMV Inc. (IMV) CEO Andrew Hall on Q1 2022 Results - Earnings Call Transcript
IMV Inc. (NASDAQ:IMV ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Andrew Hall – Chief Executive Officer Jeremy Graff – Chief Medical Officer Brittany Davison – Senior Vice President, Finance Joy Bessenger – Senior Vice President, Investor Relations & Corporate Strategy Conference Call Participants Joseph Pantginis – H.C. Wainwright & Co. Nick Abbott – Wells Fargo Securities Brandon Folkes – Cantor Fitzgerald Paul Stewardson – iA Capital Markets Joy Bessenger Good morning, everyone.
IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company's 2022 first quarter financial and operational results. Financial analysts are invited to join the con
IMV Financial details
IMV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0 | 0 | 0 | |
Net income per share | -3.91 | -4.41 | 0 | -5.05 | -4.61 | |
Operating cash flow per share | -2.88 | -4.21 | 0 | -4.32 | -4 | |
Free cash flow per share | -3.25 | -4.28 | 0 | -4.51 | -4.13 | |
Cash per share | 2.5 | 2.17 | 0 | 5.2 | 2.54 | |
Book value per share | 0.72 | 0.99 | 0 | 2.9 | -0.79 | |
Tangible book value per share | 0.72 | 0.99 | 0 | 2.9 | -0.79 | |
Share holders equity per share | 0.72 | 0.99 | 0 | 2.9 | -0.79 | |
Interest debt per share | 1.83 | 1.7 | 0 | 2.77 | 3.52 | |
Market cap | 308.23M | 188.07M | 0 | 90.52M | 20.27M | |
Enterprise value | 304.31M | 184.78M | -28.37M | 71.56M | 27.95M | |
P/E ratio | -18 | -8.59 | 0 | -2.41 | -0.53 | |
Price to sales ratio | 5.12K | 4.16K | 0 | 0 | 0 | |
POCF ratio | -24.44 | -9 | 0 | -2.82 | -0.61 | |
PFCF ratio | -21.68 | -8.85 | 0 | -2.71 | -0.59 | |
P/B Ratio | 97.25 | 38.1 | 0 | 4.2 | -3.07 | |
PTB ratio | 97.25 | 38.1 | 0 | 4.2 | -3.07 | |
EV to sales | 5.05K | 4.09K | -12.06K | 0 | 0 | |
Enterprise value over EBITDA | -20.49 | -9.43 | 1.05 | -2.04 | -0.73 | |
EV to operating cash flow | -24.13 | -8.85 | 1.04 | -2.23 | -0.84 | |
EV to free cash flow | -21.41 | -8.69 | 1.03 | -2.14 | -0.81 | |
Earnings yield | -0.06 | -0.12 | 0 | -0.41 | -1.9 | |
Free cash flow yield | -0.05 | -0.11 | 0 | -0.37 | -1.7 | |
Debt to equity | 2.21 | 1.52 | 0.26 | 0.91 | -4.38 | |
Debt to assets | 0.42 | 0.44 | 0.17 | 0.39 | 0.92 | |
Net debt to EBITDA | 0.26 | 0.17 | 1.05 | 0.54 | -0.2 | |
Current ratio | 2.57 | 3.06 | 5.34 | 5.01 | 2.93 | |
Interest coverage | -14.84 | -21.09 | -967.22 | -39.34 | -78.83 | |
Income quality | 0.78 | 1 | 1 | 0.88 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 112.72 | 171.87 | 5.07K | 0 | 0 | |
Research and developement to revenue | 156.73 | 321.8 | 8.87K | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.13 | 0.02 | 0.01 | 0.04 | 0.03 | |
Capex to revenue | -26.65 | -8.07 | -147.33 | 0 | 0 | |
Capex to depreciation | -6.72 | -0.9 | -0.86 | -2.59 | -1.07 | |
Stock based compensation to revenue | 20.61 | 16.05 | 514 | 0 | 0 | |
Graham number | 7.98 | 9.93 | 0 | 18.17 | 9.06 | |
ROIC | -1.43 | -1.56 | -0.68 | -0.85 | -1.69 | |
Return on tangible assets | -1.02 | -1.28 | -0.59 | -0.75 | -1.23 | |
Graham Net | -0.31 | -0.01 | 0 | 1.53 | -1.83 | |
Working capital | 8.99M | 10.1M | 35.67M | 37.13M | 18.17M | |
Tangible asset value | 3.17M | 4.94M | 30.88M | 21.54M | -6.6M | |
Net current asset value | 1.05M | 2.77M | 28.65M | 17.81M | -10.36M | |
Invested capital | 2.21 | 1.52 | 0.26 | 0.91 | -4.38 | |
Average receivables | 1.19M | 1.86M | 2.51M | 2.42M | 1.83M | |
Average payables | 2.61M | 3.34M | 3.27M | 4.18M | 3.91M | |
Average inventory | 0.5 | 0.5 | 0 | 0 | 0 | |
Days sales outstanding | 10.9K | 15.5K | 481.07K | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.03 | 0.02 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -5.4 | -4.44 | -0.89 | -1.74 | 5.83 | |
Capex per share | -0.37 | -0.07 | 0 | -0.19 | -0.13 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.65 | -1.32 | -1.19 | -0.9 | -0.01 | |
Operating cash flow per share | -1 | -1.21 | -0.84 | -1.24 | -0.01 | |
Free cash flow per share | -1.09 | -1.22 | -0.91 | -1.27 | -0.01 | |
Cash per share | 5.2 | 3.49 | 3.78 | 2.64 | 0.03 | |
Book value per share | 2.9 | 1.42 | 0.29 | -0.77 | -0.01 | |
Tangible book value per share | 2.9 | 1.42 | 0.29 | -0.77 | -0.01 | |
Share holders equity per share | 2.9 | 1.42 | 0.29 | -0.77 | -0.01 | |
Interest debt per share | 2.71 | 2.46 | 3.62 | 3.59 | 0.04 | |
Market cap | 90.52M | 115.91M | 53.87M | 43.03M | 2B | |
Enterprise value | 71.56M | 107.18M | 52.46M | 50.1M | 2.01B | |
P/E ratio | -1.85 | -2.68 | -1.38 | -1.45 | -58.24 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -12.19 | -11.63 | -7.78 | -4.21 | -317.62 | |
PFCF ratio | -11.23 | -11.59 | -7.16 | -4.12 | -307.51 | |
P/B Ratio | 4.2 | 9.91 | 22.31 | -6.81 | -303.14 | |
PTB ratio | 4.2 | 9.91 | 22.31 | -6.81 | -303.14 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -6.47 | -10.67 | -5.37 | -5.33 | -242.98 | |
EV to operating cash flow | -9.64 | -10.76 | -7.58 | -4.91 | -318.83 | |
EV to free cash flow | -8.88 | -10.72 | -6.97 | -4.8 | -308.69 | |
Earnings yield | -0.13 | -0.09 | -0.18 | -0.17 | 0 | |
Free cash flow yield | -0.09 | -0.09 | -0.14 | -0.24 | 0 | |
Debt to equity | 0.91 | 1.71 | 12.31 | -4.56 | -4.38 | |
Debt to assets | 0.39 | 0.49 | 0.73 | 0.89 | 0.92 | |
Net debt to EBITDA | 1.72 | 0.87 | 0.14 | -0.75 | -0.93 | |
Current ratio | 5.01 | 3.85 | 4.19 | 2.8 | 2.93 | |
Interest coverage | -23.92 | -33.62 | -138.6 | -12.96 | 226.05 | |
Income quality | 0.63 | 0.95 | 0.7 | 1.14 | 0.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.09 | 0 | 0.09 | 0.02 | 0.03 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -3.04 | -0.18 | -2.77 | -0.8 | -0.64 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 10.37 | 6.49 | 2.8 | 3.95 | 0.04 | |
ROIC | -0.27 | -0.32 | -0.29 | -0.34 | -0.36 | |
Return on tangible assets | -0.24 | -0.27 | -0.24 | -0.23 | -0.27 | |
Graham Net | 1.53 | 0.17 | -0.67 | -1.88 | -0.02 | |
Working capital | 37.13M | 27.13M | 27.75M | 18.25M | 18.17M | |
Tangible asset value | 21.54M | 11.7M | 2.42M | -6.32M | -6.6M | |
Net current asset value | 17.81M | 7.53M | -1.63M | -10.22M | -10.36M | |
Invested capital | 0.91 | 1.71 | 12.31 | -4.56 | -4.38 | |
Average receivables | 1.8M | 2.09M | 2.19M | 1.86M | 1.85M | |
Average payables | 2.31M | 2.31M | 0 | 0 | 1.59M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.57 | -0.93 | -4.04 | 1.18 | 1.3 | |
Capex per share | -0.09 | 0 | -0.07 | -0.03 | 0 |
IMV Frequently Asked Questions
What is IMV Inc. stock symbol ?
IMV Inc. is a CA stock , located in Dartmouth of Ns and trading under the symbol IMV
What is IMV Inc. stock quote today ?
IMV Inc. stock price is $- today.
Is IMV Inc. stock public?
Yes, IMV Inc. is a publicly traded company.